1-Year Data on Omidubicel Shows Sustained Benefits, Reduced Infection Rates
There was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.
Cell Therapy for AML Granted Fast Track Designation
A phase 1/2a clinical trial assessing VOR33 is currently enrolling.